Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients
Alexandra J. van den Broek(The Netherlands Cancer Institute), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Hester S. A. Oldenburg(The Netherlands Cancer Institute), Marjanka K. Schmidt(University of Cambridge), Laura van ‘t Veer, Emiel J. Rutgers(Oncode Institute), Flora E. van Leeuwen(The Netherlands Cancer Institute), Pieter J. Westenend(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Sabine Siesling(Netherlands Comprehensive Cancer Organisation), Linetta B. Koppert(Erasmus MC Cancer Institute), Jan J. Jobsen(Medisch Spectrum Twente), Adri C. Voogd(Maastricht University Medical Centre), Vincent T.H.B.M. Smit(Leiden University Medical Center), Nicola S. Russell(The Netherlands Cancer Institute)
Cited by 58
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k